These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38926964)

  • 1. [The Effecacy and Safety of Daratumumab Based Regimens in Relapsed/Refractory Multiple Myeloma: A Single-Center Real-World Data Analysis].
    Zeng HY; Lin ZJ; Li ZF; Liu L; Deng MM; Xu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):763-767. PubMed ID: 38926964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
    Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.
    Han X; Jiang X; He J; Zheng G; Xiong Y; Wen Y; Yang Y; He D; Chen Q; Zhao Y; Li Y; Wu W; Cai Z
    Cancer Med; 2024 May; 13(9):e7232. PubMed ID: 38698679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
    Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
    Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
    Zhao AL; Tang WJ; Li Y; Liao Y; Li H; Wang J; Shen K; Yang YF; Xu J; Zhang L; Zheng YH; Niu T
    Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(41):3304-3311. PubMed ID: 36319183
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
    Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H
    Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
    Cohen YC; Oriol A; Wu KL; Lavi N; Vlummens P; Jackson C; Garvin W; Carson R; Crist W; Fu J; Feng H; Xie H; Schecter J; San-Miguel J; Lonial S
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):46-54.e4. PubMed ID: 33485428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
    Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
    Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
    Jia YJ; Liu H; Wang LR; Wang T; Feng R; Chen YJ; Wang M; Guo HX; Wen L; Duan WB; Yang YZ; Wang FR; Chen YY; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):347-352. PubMed ID: 32370462
    [No Abstract]   [Full Text] [Related]  

  • 12. Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study.
    Sunami K; Murakami H; Tagashira H; Ueda H; Moriyama T; Ishikawa T; Yoshioka T; Makita M
    Int J Clin Oncol; 2020 Dec; 25(12):2151-2157. PubMed ID: 32715356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.
    Mele G; Cascavilla N; Di Renzo N; Guarini A; Mazza P; Melillo L; Pavone V; Tarantini G; Curci P; Falcone AP; Germano C; Mele A; Palazzo G; Palumbo G; Reddiconto G; Rossini B; Specchia G; Musto P; Pastore D
    Ann Hematol; 2022 Aug; 101(8):1727-1739. PubMed ID: 35587825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
    Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
    Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
    Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
    Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
    Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
    Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of efficacy and safety of daratumumab-containing regimen in relapsed and refractory multiple myeloma patients].
    Yu QR; Zhou X; Wu HY; Hao LM; Li XM; Zhong YP
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):521-525. PubMed ID: 38317364
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
    Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
    Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.
    Harvanová Ľ; Štulajterová V; Guman T; Ladická M; Hlebašková M; Chudej J; Šimek M; Štecová N; Flochová E; Kubala J; Simančíková I; Drgoňa Ľ; Vranovský A; Wild A; Mistrík M; Bátorová A
    Neoplasma; 2021 May; 68(3):626-630. PubMed ID: 33567854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
    Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
    Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.